TB-500 appears in the literature in contexts that must be kept distinct: molecular research, preclinical models, possible clinical studies and commercial products. This guide explains the terminology and limitations without dosing, reconstitution or administration instructions.
- Declared classification: Supplier-declared peptide material
- Category: Regenerative & Tissue Research
- Catalogue presentations: 5 mg, 10 mg
- Status: research use only; availability is confirmed on enquiry
What research examines about TB-500
TB-500 is a commercial name associated with thymosin beta-4-derived materials. Relevant research examines actin binding, cell migration, angiogenesis and tissue responses in preclinical models.
A mention in a scientific paper describes the molecule or model evaluated in that study. It does not automatically confirm the identity, purity, quantity, sterility or suitability of a commercial vial.
Investigated mechanism
The attributed mechanism depends on the exact sequence supplied. Analytical identity and the distinction between commercial TB-500 and full-length thymosin beta-4 must therefore be documented for every batch.
Responsible interpretation starts with the species, experimental system, comparator, method and endpoint. In-vitro findings, animal evidence and human-study results are not interchangeable.
How strong is the evidence?
The name TB-500 does not by itself define composition. Study information cannot be applied to a product until sequence and quantity have been confirmed.
PeptidaLab does not turn preliminary results into personal promises. Where an authorised medicine uses a similar active substance, that authorisation applies to the specific product, manufacturer, indication and regulated supply chain—not to every material carrying the same name.
What should be verified for the batch?
A useful dossier links the vial unambiguously to its batch number, declared identity, analytical method, quantity, analysis date, issuing laboratory, storage conditions and chain of custody. HPLC and mass spectrometry can answer different questions; no isolated percentage establishes every product characteristic.
Associated catalogue pages
Frequently asked questions
What is TB-500?
TB-500 is listed in the catalogue as supplier-declared peptide material. That classification describes a research context, not a medical indication.
Which TB-500 presentations are listed?
The catalogue lists: 5 mg, 10 mg. Commercial availability remains blocked pending legal and documentary review.
Is TB-500 approved for human use?
This page describes only the scientific context of an RUO material. A publication about a molecule does not authorise the catalogue product for use in humans.
Method, sources and limitations
This material was written originally and reviewed to distinguish preclinical findings, human studies and commercial status. For legislation and authorisation, consult Directive 2001/83/EC, the EMA and relevant primary scientific literature.
For research use only (RUO). Not for use in humans. This article is not medical or legal advice and provides no instructions for use.